Cargando…

Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway

PURPOSE: To investigate the effect of 20(S)-ginsenoside Rh2 (Rh2) on anti HepG2 liver cancer cells and HepG2 cell-derived xenograft tumors, and explore the underlying mechanisms. MATERIALS AND METHODS: The activity of total HDACs and HAT were assessed with a HDACs colorimetric kit. Expression of HDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiang, Shi Qing, Qin, Gao Chao, Jing, Li, Qiang, Feng Zi, Mei, Qin Hong, Long, Chen Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629470/
https://www.ncbi.nlm.nih.gov/pubmed/34452568
http://dx.doi.org/10.31557/APJCP.2021.22.8.2529
_version_ 1784607212143902720
author Qiang, Shi Qing
Qin, Gao Chao
Jing, Li
Qiang, Feng Zi
Mei, Qin Hong
Long, Chen Di
author_facet Qiang, Shi Qing
Qin, Gao Chao
Jing, Li
Qiang, Feng Zi
Mei, Qin Hong
Long, Chen Di
author_sort Qiang, Shi Qing
collection PubMed
description PURPOSE: To investigate the effect of 20(S)-ginsenoside Rh2 (Rh2) on anti HepG2 liver cancer cells and HepG2 cell-derived xenograft tumors, and explore the underlying mechanisms. MATERIALS AND METHODS: The activity of total HDACs and HAT were assessed with a HDACs colorimetric kit. Expression of HDAC1, HDAC2, HDAC6, p-ERK, ERK, p-P38, P38, p-JNK and JNK proteins was tested by Western blotting.H3K9 and H3K14 proteins were also checked by immunofluorescence, changes in cell cycle distribution with flow cytometry, cell apoptosis with annexin V-FTIC/PI double staining. Activity of Renilla luciferase (HIF) was detected using the Luciferase Reporter Assay system reagent. Gene expression for CyclinD1, Bcl-2, Bax, HIF, IL-1, IL-6, IL-10 and TNF-α was tested by q-PCR. Expression levels of CD31 and Ki-67 was tested by immunohistochemical staining. RESULTS: Total HDAC activity was decreased and total histone acetyltransferase (HAT)activity was increased in a time-dependent manner. Expression of HDAC1 and p-JNK proteins was significantly increased, expression levels of p-ERK was decreased. H3K9 and H3K14 fluorescence protein were increased. Flow cytometric analysis of the cell cycle revealed that the percentage of cells in the G0/G1 phase in the treatment group(64.35±1.36%) was significantly increased compared with the untreated group(61.61±1.23%).The apoptotic rate of the HepG2 group was 10.03±1.92%, which increased to 17.87±1.67% in the treatment group. Expression levels of the transcription factor HIF were also increased in HepG2 cells following induction by Rh2. Expression of CyclinD1 and Bcl-2 at the genetic level was significantly decreased, while expression levels of Bax, HIF, IL-1, IL-6, IL-10 and TNF-α was increased. In vivo, the expression levels of both CD31 and Ki-67 proteins were significantly down-regulated in the treatment group compared with the control group. CONCLUSIONS: The effects of Rh2 were suggested to occur through the inhibition of total HDAC activity, which subsequently induced MAPK signaling and down-regulated the expression of HIF.
format Online
Article
Text
id pubmed-8629470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-86294702021-12-03 Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway Qiang, Shi Qing Qin, Gao Chao Jing, Li Qiang, Feng Zi Mei, Qin Hong Long, Chen Di Asian Pac J Cancer Prev Research Article PURPOSE: To investigate the effect of 20(S)-ginsenoside Rh2 (Rh2) on anti HepG2 liver cancer cells and HepG2 cell-derived xenograft tumors, and explore the underlying mechanisms. MATERIALS AND METHODS: The activity of total HDACs and HAT were assessed with a HDACs colorimetric kit. Expression of HDAC1, HDAC2, HDAC6, p-ERK, ERK, p-P38, P38, p-JNK and JNK proteins was tested by Western blotting.H3K9 and H3K14 proteins were also checked by immunofluorescence, changes in cell cycle distribution with flow cytometry, cell apoptosis with annexin V-FTIC/PI double staining. Activity of Renilla luciferase (HIF) was detected using the Luciferase Reporter Assay system reagent. Gene expression for CyclinD1, Bcl-2, Bax, HIF, IL-1, IL-6, IL-10 and TNF-α was tested by q-PCR. Expression levels of CD31 and Ki-67 was tested by immunohistochemical staining. RESULTS: Total HDAC activity was decreased and total histone acetyltransferase (HAT)activity was increased in a time-dependent manner. Expression of HDAC1 and p-JNK proteins was significantly increased, expression levels of p-ERK was decreased. H3K9 and H3K14 fluorescence protein were increased. Flow cytometric analysis of the cell cycle revealed that the percentage of cells in the G0/G1 phase in the treatment group(64.35±1.36%) was significantly increased compared with the untreated group(61.61±1.23%).The apoptotic rate of the HepG2 group was 10.03±1.92%, which increased to 17.87±1.67% in the treatment group. Expression levels of the transcription factor HIF were also increased in HepG2 cells following induction by Rh2. Expression of CyclinD1 and Bcl-2 at the genetic level was significantly decreased, while expression levels of Bax, HIF, IL-1, IL-6, IL-10 and TNF-α was increased. In vivo, the expression levels of both CD31 and Ki-67 proteins were significantly down-regulated in the treatment group compared with the control group. CONCLUSIONS: The effects of Rh2 were suggested to occur through the inhibition of total HDAC activity, which subsequently induced MAPK signaling and down-regulated the expression of HIF. West Asia Organization for Cancer Prevention 2021-08 /pmc/articles/PMC8629470/ /pubmed/34452568 http://dx.doi.org/10.31557/APJCP.2021.22.8.2529 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Qiang, Shi Qing
Qin, Gao Chao
Jing, Li
Qiang, Feng Zi
Mei, Qin Hong
Long, Chen Di
Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway
title Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway
title_full Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway
title_fullStr Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway
title_full_unstemmed Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway
title_short Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway
title_sort anticancer effect of rh2, a histone deacetylase inhibitor, in hepg2 cells and hepg2 cell-derived xenograft tumors occurs via the inhibition of hdacs and activation of the mapk signaling pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629470/
https://www.ncbi.nlm.nih.gov/pubmed/34452568
http://dx.doi.org/10.31557/APJCP.2021.22.8.2529
work_keys_str_mv AT qiangshiqing anticancereffectofrh2ahistonedeacetylaseinhibitorinhepg2cellsandhepg2cellderivedxenografttumorsoccursviatheinhibitionofhdacsandactivationofthemapksignalingpathway
AT qingaochao anticancereffectofrh2ahistonedeacetylaseinhibitorinhepg2cellsandhepg2cellderivedxenografttumorsoccursviatheinhibitionofhdacsandactivationofthemapksignalingpathway
AT jingli anticancereffectofrh2ahistonedeacetylaseinhibitorinhepg2cellsandhepg2cellderivedxenografttumorsoccursviatheinhibitionofhdacsandactivationofthemapksignalingpathway
AT qiangfengzi anticancereffectofrh2ahistonedeacetylaseinhibitorinhepg2cellsandhepg2cellderivedxenografttumorsoccursviatheinhibitionofhdacsandactivationofthemapksignalingpathway
AT meiqinhong anticancereffectofrh2ahistonedeacetylaseinhibitorinhepg2cellsandhepg2cellderivedxenografttumorsoccursviatheinhibitionofhdacsandactivationofthemapksignalingpathway
AT longchendi anticancereffectofrh2ahistonedeacetylaseinhibitorinhepg2cellsandhepg2cellderivedxenografttumorsoccursviatheinhibitionofhdacsandactivationofthemapksignalingpathway